CTOR (Citius Oncology) Total Liabilities: $65.43 Mil (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.63
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Total Liabilities?

Citius Oncology CTOR -6.07% 10 Total Liabilities is $65.43 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Citius Oncology's Total Liabilities for the quarter that ended in Mar. 2026 was $65.43 Mil.

Citius Oncology's quarterly Total Liabilities declined from Sep. 2025 ($56.08 Mil) to Dec. 2025 ($51.56 Mil) but then increased from Dec. 2025 ($51.56 Mil) to Mar. 2026 ($65.43 Mil).

Citius Oncology's annual Total Liabilities increased from Sep. 2023 ($22.20 Mil) to Sep. 2024 ($38.23 Mil) and increased from Sep. 2024 ($38.23 Mil) to Sep. 2025 ($56.08 Mil).

Citius Oncology Total Liabilities Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Total Liabilities Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Total Liabilities
6.42 22.20 38.23 56.08

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.80 59.31 56.08 51.56 65.43
CTOR
10GF Score
Citius Oncology Inc CTOR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Citius Oncology's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=49.492+(3.8+8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.785+0+0)
=56.08

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=100.943-44.866
=56.08

Citius Oncology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=58.812+(3.8+9.3258734068513E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.818+0+0)
=65.43

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=100.699-35.269
=65.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $65.43 Mil mean?
Citius Oncology (CTOR) has a Total Liabilities of $65.43 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Citius Oncology and its competitors.
Is Citius Oncology's Total Liabilities too high?
Citius Oncology's current Total Liabilities is $65.43 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Total Liabilities compare to INCR and BGM?
Citius Oncology's Total Liabilities of $65.43 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Citius Oncology and its competitors. Citius Oncology's current Total Liabilities is $65.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Total Liabilities of $65.43 Mil. The current Total Liabilities is $65.43 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Total Liabilities is $65.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price